A biopharmaceutical company and the Miller School of Medicine at the University of Miami have announced a partnership to conduct a phase 1/2a clinical trial of ALZN002, a treatment for Alzheimer’s-related dementia.
According to a release from Alzamend Neuro, ALZN002 is a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s disease.
“We strongly believe that the ALZN002 patient-specific immunotherapeutic vaccine has the potential of fostering